The number of antibiotic-resistant strains continues to rise rapidly. Statistics from the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA) point to alarming trends that are...
It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!
Patients with heart failure and reduced ejection fraction (HF-REF) treated with an investigational angiotensin receptor neprilysin Inhibitor (ARNI) are more likely to reduce cardiovascular death and heart failure hospitalization than...
Teens who received the collaborative care intervention in primary care had significantly greater improvements in depressive symptoms than teens who were receiving treatment as usual.

FDA APPROVALS
ER opioid analgesic with ...

An extended-release (ER) opioid analgesic, hydrocodone bitartrate (Hysingla ER, Purdue Pharma) has been approved by FDA ...

New drug approved by FDA for the ...
Newly approved blood test predicts ...
FDA approves Cyramza in combination ...

CLINICAL
Tumor treating fields with ...

Adding tumor treating fields (TTFields) therapy to temozolomide significantly increases progression-free survival (PFS) ...

ER opioid analgesic with ...
Skin cancer treatment costs soar
$125-million priority review voucher ...

DRUGS IN PERSPECTIVE
Drugs in Perspective: Otezla ...

Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase 4 (PDE4), was approved by FDA on March 21, 2014, for ...

Drugs in Perspective: Zykadia ...
Drugs in Perspective: Dalvance
Drugs in Perspective: Tasimelteon ...

Latest Tweets Follow